Before switching to the listing route, TPG-backed Sai Life Sciences had explored the sale of a controlling stake in the firm and conducted a sale process, which resulted in Bain Capital emerging as the front-runner in the final leg, according to a January 25 report by Moneycontrol. But talks between both parties did not fructify into a deal.